SeaStar Medical Holding Corp

Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, CO.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company was founded on June 6, 2007 and is headquartered in Denver, CO.

DENVER, June 20, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces enrollment of the first patient in the NEUTRALIZE-AKI pivotal clinical trial to evaluate the safety and efficacy of its patented, first-in-class, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill adults with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT).

First Patient Enrolled in SeaStar Medical's Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical (NASDAQ: ICU ) stock is on the rise Thursday as the medical technology company's shares see plenty of activity today. During the early trading hours, some 6 million shares of ICU stock changed hands.

Why Is SeaStar Medical (ICU) Stock Up 80% Today?

DENVER, May 15, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three months ended March 31, 2023 and provides a business update.

SeaStar Medical Reports First Quarter 2023 Financial Results and Provides a Business Update

SeaStar Medical (NASDAQ: ICU ) stock is falling on Wednesday after the medical technology company got an update from the FDA. What's hitting ICU stock is the FDA not approving its Humanitarian Device Exemption (HDE) application for pediatric Selective Cytopheretic Device ( SCD ).

Why Is SeaStar Medical (ICU) Stock Down 32% Today?

DENVER, May 10, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Eric Schlorff, CEO, will present a company overview at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 2:30 p.m. Eastern time. The conference is being held at the New York Hilton Midtown.

SeaStar Medical to Present at the JMP Securities Life Sciences Conference on May 16, 2023

DENVER, March 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides a business update and reports financial results for the year ended December 31, 2022.

SeaStar Medical Reports 2022 Financial Results and Provides a Business Update

DENVER, March 15, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Eric Schlorff, Chief Executive Officer, and Kevin Chung, M.D., Chief Medical Officer, will present a company overview at the Emerging Growth Virtual Conference on Wednesday, March 22, 2023 at 2:15 p.m. Eastern time.

SeaStar Medical to Present at the Emerging Growth Virtual Conference on March 22, 2023

DENVER, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Kevin Chung, M.D., Chief Medical Officer, will discuss the Company's Selective Cytopheretic Device (SCD) in a presentation at the 5 th Chronic Kidney Disease Drug Development Summit (CKD5) in Boston on March 7, 2023 at 10 a.m. Eastern Time.

SeaStar Medical's Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit

The NEUTRALIZE-AKI study will evaluate safety and efficacy of the SCD 's ability to target and neutralize the highly activated proinflammatory neutrophils and monocytes that drive hyperinflammation

SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury

DENVER, Feb. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces it will hold a conference call to discuss business updates including the recent FDA approval to conduct a pivotal trial evaluating the effectiveness of its Selective Cytopheretic Device (SCD) in reducing hyperinflammation in adults with acute kidney injury (AKI) and an update regarding the Humanitarian Device Exemption (HDE) submission for market approval for use of the SCD for critically ill children with AKI.

SeaStar Medical to Hold Business Update Conference Call on February 15, 2023

Patient e nrollment in pivotal clinical study expected to begin in March

SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury

Building upon demonstrated clinical success, the pivotal study will evaluate the Selective Cytopheretic Device in adults with AKI requiring CKR T

SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients

DENVER, COLORADO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq:ICU), (“SeaStar Medical” or the “Company”), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced the appointment of Thomas R. Mullen as Vice President of Operations and Product Development. Mr. Mullen is a proven medical device professional with 30 years of experience leading business operations, manufacturing, engineering, product development and regulatory remediation.

SeaStar Medical Bolsters Operational Expertise with Appointment of Thomas R. Mullen as Vice President of Operations and Product Development

DENVER, COLORADO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq:ICU), (“SeaStar Medical” or the “Company”), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced the appointment of Rick Barnett as Chairman of the Company's Board of Directors. Mr. Barnett has served on the SeaStar Medical Board as a Director since January 2021, and currently serves as Chair of the Compensation Committee and a member of the Audit Committee.

SeaStar Medical Appoints Rick Barnett as Chairman of the Board of Directors

– The SCD is currently being evaluated by the FDA for a Humanitarian Device Exemption (HDE) marketing approval for use in children (> 20 kgs) with AKI

SeaStar Medical's Lead Product Candidate, the Selective Cytopheretic Device (SCD), Included in Consensus Statement for Pediatric Acute Kidney Injury in First Pediatric Acute Disease Quality Initiative (ADQI) Meeting

– Company advancing clinically proven platform therapy , the Selective Cytopheretic Device (SCD ), to address the life-threatening consequences of hyperinflammation

SeaStar Medical (NASDAQ: ICU) Commences Trading on Nasdaq Capital Market and Outlines Corporate Strategy and Near-Term Catalysts

News for SeaStar Medical Holding Corp Stock (ICU)